Global Health News: Biogen's Strategic Shifts and Ebola Vaccine Efforts

Source Summary

Biogen discontinues Apellis programs post $5.6B acquisition, reallocating resources to Empaveli and Syfovre. U.S. begins Ebola Bundibugyo vaccine efforts as outbreak grows in Africa. The FDA tightens foreign tobacco oversight and declines Sobi's gout therapy approval due to manufacturing concerns. Global cocaine and meth trade booms, a UN report finds.